Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease.
Cuchel, M., Meagher, E., du Toit Theron, H., Blom, D., Marais, A., Hegele, R., et al. (2013). Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. THE LANCET, 381(9860), 40-46 [10.1016/S0140-6736(12)61731-0].
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
CEFALU', Angelo Baldassare;AVERNA, Maurizio;NOTO, Davide
2013-01-01
Abstract
Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial.pdf
Solo gestori archvio
Descrizione: Articolo
Dimensione
222.34 kB
Formato
Adobe PDF
|
222.34 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
